Base de dados : MEDLINE
Pesquisa : D27.505.954.796.050 [Categoria DeCS]
Referências encontradas : 9892 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 990 ir para página                         

  1 / 9892 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29401500
[Au] Autor:Shields MD; ALQahtani F; Rivey MP; McElnay JC
[Ad] Endereço:Centre for Infection and Immunity. School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom.
[Ti] Título:Mobile direct observation of therapy (MDOT) - A rapid systematic review and pilot study in children with asthma.
[So] Source:PLoS One;13(2):e0190031, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We describe, for the first time, the use of a mobile device platform for remote direct observation of inhaler use and technique. The research programme commenced with a rapid systematic review of mobile device (or videophone) use for direct observation of therapy (MDOT). Ten studies (mainly pilots) were identified involving patients with tuberculosis, sickle cell disease and Alzheimer's disease. New studies are ongoing (ClinicalTrials.gov website) in TB, stroke, sickle cell disease, HIV and opioid dependence. Having identified no prior use of MDOT in inhaler monitoring, we implemented a feasibility study in 12 healthy volunteer children (2-12 years; 8 females and 4 males) over a period of 14 days, with twice daily video upload of their 'dummy' inhaler use. Two children uploaded 100% of the requested videos, with only one child having an inhaler upload rate of <75%. The quality of uploaded videos was generally good (only 1.7% of unacceptable quality for evaluation). The final aspect of the research was a pilot study using MDOT (6 weeks) in 22 children with difficult to treat asthma. Healthcare professionals evaluated inhaler technique using uploaded videos and provided telephone instruction on improving inhaler use. The main outcomes were assessed at week 12 post initiation of MDOT. By week 5, all children still engaging in MDOT (n = 18) were judged to have effective inhaler technique. Spirometry values did not vary to a significantly significant degree between baseline and 12 weeks (P>0.05), however, mean fraction of exhaled nitric oxide (FeNO) values normalised (mean 38.7 to 19.3ppm) and mean Asthma Control Test values improved (13.1 to mean 17.8). Feedback from participants was positive. Overall the findings open up a new paradigm in device independent (can be used for any type of inhaler device) monitoring, providing a platform for evaluating / improving inhaler use at home.
[Mh] Termos MeSH primário: Antiasmáticos/uso terapêutico
Asma/tratamento farmacológico
Terapia Diretamente Observada
Smartphone
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Feminino
Seres Humanos
Masculino
Nebulizadores e Vaporizadores
Cooperação do Paciente
Projetos Piloto
Ensaios Clínicos Controlados Aleatórios como Assunto
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180206
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190031


  2 / 9892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29179850
[Au] Autor:Young G
[Ad] Endereço:c/o La revue de l'infirmière, 65 rue Camille-Desmoulins, 92442, Issy-les-Moulineaux Cedex, France. Electronic address: ghislainecy@icloud.com.
[Ti] Título:A nurse-led review of a child with asthma.
[So] Source:Rev Infirm;66(236):45-46, 2017 Dec.
[Is] ISSN:1293-8505
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Eliza is a practice nurse working in a large general practice in England. She is a trained nurse with additional qualifications in chronic disease management, and is also a registered prescriber. This means she can initiate or repeat medical prescriptions. Today Eliza is reviewing her asthma patients.
[Mh] Termos MeSH primário: Asma/enfermagem
Avaliação em Enfermagem
[Mh] Termos MeSH secundário: Antiasmáticos/uso terapêutico
Asma/tratamento farmacológico
Criança
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE


  3 / 9892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29446292
[Au] Autor:Shahlavi­Monavvar P; Mobasher-Jannat A
[Ad] Endereço:Tabriz University of Medical Sciences, Tabriz, Iran
[Ti] Título:Mepolizumab for Eosinophilic COPD.
[So] Source:N Engl J Med;378(7):681, 2018 02 15.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Antiasmáticos
Anticorpos Monoclonais Humanizados
[Mh] Termos MeSH secundário: Asma
Eosinófilos
Seres Humanos
Doença Pulmonar Obstrutiva Crônica
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Antibodies, Monoclonal, Humanized); 90Z2UF0E52 (mepolizumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180216
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1715454


  4 / 9892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29446291
[Au] Autor:Xia Y; Li W; Shen H
[Ad] Endereço:Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
[Ti] Título:Mepolizumab for Eosinophilic COPD.
[So] Source:N Engl J Med;378(7):680-1, 2018 02 15.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Antiasmáticos
Anticorpos Monoclonais Humanizados
[Mh] Termos MeSH secundário: Asma
Eosinófilos
Seres Humanos
Doença Pulmonar Obstrutiva Crônica
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Antibodies, Monoclonal, Humanized); 90Z2UF0E52 (mepolizumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180216
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1715454


  5 / 9892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443666
[Au] Autor:Sciurba FC; Bradford ES; Pavord ID
[Ad] Endereço:University of Pittsburgh, Pittsburgh, PA sciurbafc@upmc.edu
[Ti] Título:Mepolizumab for Eosinophilic COPD.
[So] Source:N Engl J Med;378(7):681-683, 2018 02 15.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Antiasmáticos
Anticorpos Monoclonais Humanizados
[Mh] Termos MeSH secundário: Asma
Eosinófilos
Seres Humanos
Doença Pulmonar Obstrutiva Crônica
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Antibodies, Monoclonal, Humanized); 90Z2UF0E52 (mepolizumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1715454


  6 / 9892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29363343
[Au] Autor:White C; Wright A; Brightling C
[Ad] Endereço:a Institute for Lung Health, NIHR Leicester Biomedical Research Centre, Department of Infection, Immunity & Inflammation , University of Leicester and University Hospitals of Leicester NHS Trust , Leicester , UK.
[Ti] Título:Fevipiprant in the treatment of asthma.
[So] Source:Expert Opin Investig Drugs;27(2):199-207, 2018 Feb.
[Is] ISSN:1744-7658
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Asthma is common and in many, particularly those with more severe disease, there remains a substantial unmet need. Success with biologics targeting eosinophilic inflammation underscore the value of treating inflammation in asthma beyond corticosteroids. Fevipiprant (QAW039) is an oral treatment for asthma. It competitively and reversibly antagonises the prostaglandin D2 receptor 2 (DP2) expressed on inflammatory and structural cells. Areas covered: We reviewed fevipiprant's mode of action and efficacy against other current and emerging pharmacological interventions for moderate-to-severe asthma. We undertook a literature review using the PubMed/Medline database, the U.S. National Library of Medicine's Clinical Trials website and from manufacturers' press releases with the search terms: 'QAW039', 'Fevipiprant', 'CRTH2 antagonists', 'DP2', 'DP1', 'monoclonal antibody', 'eosinophil' with 'asthma' plus the names of individual drugs. Three Phase 2 trials have been conducted and three Phase 3 trials (NCT02563067, NCT03052517, NCT02555683) are in progress. To date Fevipiprant's greatest success has been in targeting severe eosinophilic asthma. Expert opinion: Fevipiprant presents the possibility of a new orally active therapy for asthma. If successful in phase 3 trials it will have an enormous impact on the treatment paradigm for asthma and will potentially widen access for pre-biologic treatment to a larger population.
[Mh] Termos MeSH primário: Antiasmáticos/uso terapêutico
Asma/tratamento farmacológico
Ácidos Indolacéticos/uso terapêutico
Piridinas/uso terapêutico
[Mh] Termos MeSH secundário: Administração Oral
Antiasmáticos/administração & dosagem
Antiasmáticos/farmacologia
Asma/fisiopatologia
Eosinófilos/metabolismo
Seres Humanos
Ácidos Indolacéticos/administração & dosagem
Ácidos Indolacéticos/farmacologia
Inflamação/tratamento farmacológico
Inflamação/fisiopatologia
Piridinas/administração & dosagem
Piridinas/farmacologia
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Indoleacetic Acids); 0 (Pyridines); 0 (fevipiprant)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.1080/13543784.2018.1432592


  7 / 9892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29388830
[Au] Autor:de Jong E; Bosco A
[Ad] Endereço:1 Telethon Kids Institute University of Western Australia Subiaco, Australia.
[Ti] Título:Dissecting Asthma Transcriptomics: Does Site Matter?
[So] Source:Am J Respir Cell Mol Biol;58(2):144-146, 2018 02.
[Is] ISSN:1535-4989
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Corticosteroides/uso terapêutico
Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico
Antiasmáticos/uso terapêutico
Asma/tratamento farmacológico
Asma/patologia
Transcriptoma/genética
[Mh] Termos MeSH secundário: Asma/genética
Perfilação da Expressão Gênica
Seres Humanos
Linfócitos T Auxiliares-Indutores/imunologia
[Pt] Tipo de publicação:EDITORIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Adrenergic beta-2 Receptor Agonists); 0 (Anti-Asthmatic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1165/rcmb.2017-0360ED


  8 / 9892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29334288
[Au] Autor:Ntontsi P; Papathanassiou E; Loukides S; Bakakos P; Hillas G
[Ad] Endereço:a 2nd Respiratory Medicine Department , National and Kapodistrian University of Athens, Medical School, Attikon Hospital , Athens , Greece.
[Ti] Título:Targeted anti-IL-13 therapies in asthma: current data and future perspectives.
[So] Source:Expert Opin Investig Drugs;27(2):179-186, 2018 Feb.
[Is] ISSN:1744-7658
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The identification of patients with severe asthma who will benefit from a personalized management approach remains an unmet need. Interleukin-13 (IL-13) is a cytokine possessing a significant role in asthma pathogenesis and progression of disease. Humanised monoclonal antibodies against IL-13 and IL-13 and IL-4 receptors are mainly proposed as add-on therapy in patients with T 2-high inflammation with uncontrolled asthma despite maximum therapy. Areas covered: The role of IL-13 in airway inflammation in severe asthma, the targeted anti-IL-13 therapies and biomarkers that predict response to anti-IL-13 treatment are discussed. Expert opinion: New effective individualized therapies in severe asthma are urgently needed to block specific inflammatory pathways using monoclonal antibodies. Studies on anti-IL-13 therapies showed that asthmatic patients could benefit from this novel targeted therapy as far as lung function and exacerbation rate are concerned. T 2-high and especially periostin-high groups of asthmatics with moderate-to-severe uncontrolled asthma seem to compose the group that could benefit from anti-IL-13 therapy. Targeting IL-13 alone may not be sufficient to achieve asthma control. Inhibition of IL-13 and IL-4 with mabs may be more encouraging and patients will probably have additional benefits from these therapeutic interventions because of IL-13/IL-4 overlapping actions in asthma pathophysiology.
[Mh] Termos MeSH primário: Antiasmáticos/farmacologia
Asma/tratamento farmacológico
Interleucina-13/imunologia
[Mh] Termos MeSH secundário: Animais
Antiasmáticos/imunologia
Anticorpos Monoclonais Humanizados/imunologia
Anticorpos Monoclonais Humanizados/farmacologia
Asma/imunologia
Seres Humanos
Inflamação/tratamento farmacológico
Inflamação/imunologia
Terapia de Alvo Molecular
Medicina de Precisão/métodos
Receptores de Interleucina-13/imunologia
Receptores de Interleucina-4/imunologia
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Antibodies, Monoclonal, Humanized); 0 (Interleukin-13); 0 (Receptors, Interleukin-13); 0 (Receptors, Interleukin-4)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180116
[St] Status:MEDLINE
[do] DOI:10.1080/13543784.2018.1427729


  9 / 9892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29325306
[Au] Autor:Xing B; Lin JT; Tang HP; Yang L; Yuan YD; Gu YH; Chen P; Liu XJ; Zhang J; Liu HG; Wang CZ; Zhou W; Sun DJ; Chen YQ; Chen ZC; Huang M; Lin QC; Hu CP; Yang XH; Huo JM; Ye XW; Zhou X; Jiang P; Zhang W; Huang YJ; Dai LM; Liu RY; Cai SX; Xu JY; Zhou JY
[Ti] Título:[A retrospective study of the inducing factors and clinical characteristics of patients hospitalized for asthma exacerbation in China in 2013-2014].
[So] Source:Zhonghua Nei Ke Za Zhi;57(1):21-26, 2018 Jan 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To study the inducing factors and clinical characteristics of patients hospitalized for asthma exacerbation in China. Patients hospitalized for asthma exacerbation at 29 hospitals in China were retrospectively recruited during 2013-2014. Clinical data of 3 240 asthmatic patients were collected and analyzed including 1 369(42.3%) males and 1 871(57.7%) females. The patients hospitalized for asthma exacerbation counted for 2.95% (6 375/215 955) of all patients hospitalized during the same period. The leading six inducing factors, in sequence, were acute upper respiratory tract infection [42.3%(1 370/3 240)], changes of weather [22.8%(738/3 240)], noxious gas [(4.3%(140/3 240), allergy challenges [3.5%(115/3 240)], strenuous exercise [1.8%(57/3 240)], and air pollution [1.5%(49/3 240)]. In older patients, more exacerbations were induced by weather changes, yet less sensitive to allergy challenges. As to middle-aged patients, they were less sensitive to upper respiratory tract infections, however the difference was not statistically significant ( >0.05). In winter more asthma patients were induced by upper respiratory tract infections, while in autumn more patients were induced by weather changes, strenuous exercise and air pollution. In spring and summer more patients were induced by allergy challenges, but the differences failed to achieve statistical significance ( >0.05). In northern cities more patients were induced by upper respiratory infections, whereas in southern cities more by noxious gases. Allergy challenges and air pollution tended to affect more patients in northern cities, but the difference was of no significance ( >0.05). The differences of inducing factors among patients of different gender, with or without a smoking history, and with different exacerbation severity didn't show any statistical significance. The patients with severe and life-threatening exacerbations counted for 20.1% (652/3 240). The percentage of patients older than 60 years was higher in patients with severe or life-threatening exacerbations than in whose with mild or moderate exacerbations, so did the percentage of male patients, of patients with disease duration longer than 10 years, with smoking history, and with a history of hospitalization or emergency department visits due to asthma exacerbation during the last year. The acute upper respiratory tract infection ranks top among all the inducing factors. Senility, male gender, long duration of disease, smoking history, and a history of frequent hospital visits might be the risk factors for severe or life-threatening asthma exacerbations.
[Mh] Termos MeSH primário: Antiasmáticos/uso terapêutico
Asma/tratamento farmacológico
Hospitalização
Infecções Respiratórias/complicações
[Mh] Termos MeSH secundário: Poluição do Ar/efeitos adversos
Antiasmáticos/administração & dosagem
Asma/diagnóstico
Asma/epidemiologia
Asma/etiologia
China/epidemiologia
Feminino
Seres Humanos
Hipersensibilidade
Masculino
Meia-Idade
Infecções Respiratórias/epidemiologia
Estudos Retrospectivos
Fatores de Risco
Estações do Ano
Fatores Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2018.01.004


  10 / 9892 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29325305
[Au] Autor:Wang WQ; Lin JT; Zhou X; Wang CZ; Huang M; Cai SX; Chen P; Lin QC; Zhou JY; Gu YH; Yuan YD; Sun DJ; Yang XH; Yang L; Huo JM; Chen ZC; Jiang P; Zhang J; Ye XW; Liu HG; Tang HP; Liu RY; Liu CT; Zhang W; Hu CP; Chen YQ; Liu XJ; Dai LM; Zhou W; Huang YJ; Xu JY
[Ad] Endereço:Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China.
[Ti] Título:[Evaluation of asthma management from the surveys in 30 provinces of China in 2015-2016].
[So] Source:Zhonghua Nei Ke Za Zhi;57(1):15-20, 2018 Jan 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To evaluate the general level of asthma management in urban areas of China and further promote the national asthma management plan. A multi-center, cross-sectional survey was carried out in 30 provinces of China (except for Tibet) during Oct 2015 to May 2016. It's a questionnaire-based face-to-face survey which included asthma management using peak flow meter (PFM) and pulmonary function test, medication choice of maintenance therapy and asthma education. A total of 3 875 asthmatic outpatients were recruited including 2 347(60.6%) females and 1 528(39.4%) males. The mean age was (50.7±16.7) years ranging from 14 to 99. Only 10.1%(388/3 837) patients used PFM as monitoring, whereas 62.1%(2 405/3 874) patients underwent pulmonary function test during the past year. There were 57.4%(2 226/3 875) patients treated with inhaled cortical steroid plus long-acting ß(2)-agonist combinations (ICS+LABA) as daily medication. 43.3%(1 661/3 836) patients were followed up by physicians. Among this population, 1 362 asthmatic outpatients were recruited, who also took part in the asthma control survey in 2007-2008 in 10 cities. In this subgroup, 17.9%(244/1 360) were tested by PFM and 66.6%(907/1 362) by pulmonary function test during last year. As to the medication, 63.1%(860/1 362) selected ICS+LABA for daily control. There were 50.4%(685/1 359) patients in the follow-up cohort by physicians. Compared to the similar survey conducted in 2007-2008, the proportion of patients with ICS+LABA regimen and follow-up by physicians were markedly higher, while the rate of PFM use did not have significant improvement. Although the present level of asthma management in China is still far from ideal, asthma management has improved compared to 8 years ago. Yet the use of PFM does not significantly improve. Asthma action plan and application of PFM should be further promoted to improve the level of asthma management.
[Mh] Termos MeSH primário: Corticosteroides/administração & dosagem
Antiasmáticos/uso terapêutico
Asma/tratamento farmacológico
Pacientes Ambulatoriais/estatística & dados numéricos
[Mh] Termos MeSH secundário: Administração por Inalação
Adulto
Idoso
Asma/diagnóstico
Asma/epidemiologia
China/epidemiologia
Cidades
Estudos Transversais
Feminino
Seres Humanos
Masculino
Meia-Idade
Médicos
Inquéritos e Questionários
População Urbana
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anti-Asthmatic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2018.01.003



página 1 de 990 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde